Moleculin Reports 40% CRc Rate in AML Trial, Sets Mid-2026 Data Unblinding
Event summary
- Moleculin reported a 40% preliminary blinded CRc rate in the first 30 patients of its MIRACLE trial for relapsed/refractory AML.
- The company expects to unblind interim data for 45 patients in mid-2026.
- Moleculin raised $8.3 million in Q1 2026, extending its runway into Q3 2026.
- Annamycin showed no cardiotoxicity in 90 reviewed subjects.
- New collaborations target glioblastoma and pancreatic cancer indications.
The big picture
Moleculin's interim data suggests Annamycin could address a critical gap in treating relapsed/refractory AML, particularly in venetoclax-resistant patients. The adaptive trial design and FDA alignment reduce regulatory risk, but the company's cash position remains a constraint. Success in this pivotal trial would position Annamycin as a potential frontline therapy in a $2.5 billion AML market.
What we're watching
- Trial Momentum
- Whether the 40% CRc rate in the blinded subset translates to statistically significant results after unblinding in mid-2026.
- Execution Risk
- The pace at which Moleculin can secure additional financing to fund operations beyond Q3 2026.
- Pipeline Expansion
- How quickly Annamycin can be positioned for additional indications beyond AML, particularly in glioblastoma and pancreatic cancer.
Related topics